XTRA:EXN

Stock Analysis Report

Executive Summary

Expedeon AG focuses on the development and marketing of reagents and services for life sciences and diagnostics in the United States, Europe, the United Kingdom, Asia, and internationally.

Snowflake

Fundamentals

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Expedeon's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.3%

EXN

-0.5%

DE Biotechs

2.4%

DE Market


1 Year Return

-11.1%

EXN

5.0%

DE Biotechs

2.3%

DE Market

Return vs Industry: EXN underperformed the German Biotechs industry which returned 5% over the past year.

Return vs Market: EXN underperformed the German Market which returned 2.3% over the past year.


Shareholder returns

EXNIndustryMarket
7 Day-2.3%-0.5%2.4%
30 Day-13.7%-5.5%-0.2%
90 Day0.5%-1.8%0.6%
1 Year-11.1%-11.1%5.1%5.0%5.5%2.3%
3 Year-16.7%-17.4%68.7%67.0%18.9%8.6%
5 Year-55.3%-62.0%21.6%18.8%44.8%25.1%

Price Volatility Vs. Market

How volatile is Expedeon's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Expedeon undervalued compared to its fair value and its price relative to the market?

34.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: EXN (€1.04) is trading below our estimate of fair value (€1.59)

Significantly Undervalued: EXN is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: EXN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: EXN is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate EXN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EXN is good value based on its PB Ratio (1.2x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Expedeon forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

112.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EXN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EXN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EXN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EXN's revenue (17.8% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: EXN's revenue (17.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: EXN's Return on Equity is forecast to be low in 3 years time (2.1%).


Next Steps

Past Performance

How has Expedeon performed over the past 5 years?

12.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: EXN is unprofitable, but has reduced losses over the past 5 years at a rate of 12.4% per year.

Accelerating Growth: Unable to compare EXN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EXN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: EXN has a negative Return on Equity (-2.62%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: EXN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: EXN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Expedeon's financial position?


Financial Position Analysis

Short Term Liabilities: EXN's short term assets (€10.0M) exceeds its short term liabilities (€7.2M)

Long Term Liabilities: EXN's short term assets (10.0M) exceeds its long term liabilities (8.1M)


Debt to Equity History and Analysis

Debt Level: EXN's debt to equity ratio (18.3%) is considered satisfactory

Reducing Debt: EXN's debt to equity ratio has reduced from 52.1% to 18.3% over the past 5 years.


Balance Sheet

Inventory Level: EXN has a low level of unsold assets or inventory.

Debt Coverage by Assets: EXN's debt is covered by short term assets (assets are 1.187840x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EXN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if EXN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Expedeon's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.9%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate EXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EXN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if EXN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EXN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EXN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Expedeon's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Heikki Lanckriet 0

2.3yrs

Tenure

€196,000

Compensation

Dr. Heikki Lanckriet, Ph.D. has been Chief Executive Officer of Sygnis AG since July 7, 2017, Chief Scientific Officer since August 5, 2016 and also serves as its Member of Management Board. Dr. Lanckriet  ...


CEO Compensation Analysis

Compensation vs. Market: Heikki has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the German market.

Compensation vs Earnings: Heikki's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.6yrs

Average Tenure

Experienced Management: EXN's management team is considered experienced (2.6 years average tenure).


Board Age and Tenure

2.3yrs

Average Tenure

Experienced Board: EXN's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Heikki Lanckriet

    CEO, Chief Scientific Officer & Member of Management Board

    • Tenure: 2.3yrs
    • Compensation: €196.00k
  • Nick Gee

    Chief Technical Officer

    • Tenure: 2.3yrs
  • Antonio Gómez-Almansa

    General Counsel

    • Tenure: 0yrs
  • Miguel-Antonio Viribay

    Vice President of Sales & Marketing

    • Tenure: 4.5yrs
  • Sebastian Paul

    Vice President of Finance and Administration

    • Tenure: 4.3yrs
  • David Roth

    CFO & Member of Management Board

    • Tenure: 2.6yrs
    • Compensation: €188.00k

Board Members

  • Trevor Jarman

    Member of Supervisory Board

    • Tenure: 3.3yrs
    • Compensation: €20.00k
  • Joe Fernandez

    Chairman of Supervisory Board

    • Tenure: 0.5yrs
    • Compensation: €30.00k
  • Tim McCarthy (62yo)

    Member of Supervisory Board

    • Tenure: 3.3yrs
    • Compensation: €20.00k
  • Peter Llewellyn-Davies

    Member of Supervisory Board

    • Tenure: 2.3yrs
    • Compensation: €30.00k
  • Margarita Salas

    • Tenure: 0yrs
  • Pilar de la Huerta

    Member of Supervisory Board

    • Tenure: 2.3yrs
    • Compensation: €20.00k
  • Luis Dávila

    • Tenure: 0yrs
  • Santiago Mas

    Substitute Membe of Supervisory Board

    • Tenure: 0yrs
  • Hansjörg Plaggemars

    Member of Supervisory Board

    • Tenure: 0.3yrs

Company Information

Expedeon AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Expedeon AG
  • Ticker: EXN
  • Exchange: XTRA
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €53.622m
  • Shares outstanding: 51.56m
  • Website: https://www.expedeon.com

Number of Employees


Location

  • Expedeon AG
  • Waldhofer Str. 104
  • Heidelberg
  • 69123
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EXNXTRA (XETRA Trading Platform)YesOrdinary Bearer SharesDEEURDec 2012
EXNDB (Deutsche Boerse AG)YesOrdinary Bearer SharesDEEURDec 2012
SYGW.FOTCPK (Pink Sheets LLC)YesOrdinary Bearer SharesUSUSDDec 2012
0QBELSE (London Stock Exchange)YesOrdinary Bearer SharesGBEURDec 2012
EXNNDBATS-CHIXE (BATS 'Chi-X Europe')NPVGBEUROct 2019

Biography

Expedeon AG focuses on the development and marketing of reagents and services for life sciences and diagnostics in the United States, Europe, the United Kingdom, Asia, and internationally. It offers a seri ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/06 23:14
End of Day Share Price2019/10/02 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.